secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2022-09-07T23:59:59+00:00
Accession:  0001193125-22-239422
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara sells PDE9 program (tovinontrine) to Cardurion for $34.75M upfront plus milestones
--------------------------------------------------------------------------------

- Imara to receive $34.75M upfront at closing for tovinontrine and all PDE9 assets; plus $250k previously paid.
- Potential milestone payments: $10M for proof-of-concept/clinical milestones, $50M for regulatory/commercial milestones.
- Transaction requires stockholder approval; Board unanimously approved; termination fee of $1.5M.
- Retention agreements amended for CEO Rahul Ballal and CFO/COO Michael Gray, with 50% payable on definitive agreement and 50% on closing.
- Company will continue evaluating strategic alternatives post-sale, including possible liquidation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522239422/0001193125-22-239422-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522239422/d396958d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-239422

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer